0      0

JL1112ES - JL1112ES: Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)

‐ Oct 27, 2023 2:00pm

Full author listing

Sara M. Tolaney,1 Aditya Bardia,2 Frederik Marmé,3 Javier Cortes,4 Peter Schmid,5 Delphine Loirat,6 Olivier Trédan,7 Eva Ciruelos,8 Florence Dalenc,9 Patricia Gómez Pardo,10 Komal L. Jhaveri,11 Rosemary Delaney,12 Theresa Valdez,12 Oh Kyu Yoon,12 Hao Wang,12Wendy Verret,12 Hope S. Rugo13 

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 3Medical Faculty Mannheim, Heidelberg University, Department of Obstetrics and Gynaecology, Heidelberg, Germany; 4Medical Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid & Barcelona, Spain, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain; 5Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 6Institut Curie, Medical Oncology Department and D3i, Paris, France; 7Medical Oncology Department, Centre Léon Bérard, Lyon, France; 8Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; 9Institut Claudius Régaud, IUCT-Oncopole, Toulouse, France; 10Hospital Universitari Vall D'Hebron, Barcelona, Spain; 11Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY; 12Gilead Sciences Inc, Foster City, CA; 13Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA


You must be logged in and own this session in order to post comments.